FI101538B1 - Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-metyyli-1-piperatsinyyli)-10H-tieno[2,3-b][1,5]bentsodiatsepiinijohdannaisten valmistamiseksi - Google Patents

Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-metyyli-1-piperatsinyyli)-10H-tieno[2,3-b][1,5]bentsodiatsepiinijohdannaisten valmistamiseksi

Info

Publication number
FI101538B1
FI101538B1 FI932445A FI932445A FI101538B1 FI 101538 B1 FI101538 B1 FI 101538B1 FI 932445 A FI932445 A FI 932445A FI 932445 A FI932445 A FI 932445A FI 101538 B1 FI101538 B1 FI 101538B1
Authority
FI
Finland
Prior art keywords
methyl
thieno
piperazinyl
preparation
therapeutically useful
Prior art date
Application number
FI932445A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI932445A (fi
FI101538B (fi
FI932445A0 (fi
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of FI932445A0 publication Critical patent/FI932445A0/fi
Publication of FI932445A publication Critical patent/FI932445A/fi
Application granted granted Critical
Publication of FI101538B publication Critical patent/FI101538B/fi
Publication of FI101538B1 publication Critical patent/FI101538B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI932445A 1992-05-29 1993-05-28 Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-metyyli-1-piperatsinyyli)-10H-tieno[2,3-b][1,5]bentsodiatsepiinijohdannaisten valmistamiseksi FI101538B1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (4)

Publication Number Publication Date
FI932445A0 FI932445A0 (fi) 1993-05-28
FI932445A FI932445A (fi) 1993-11-30
FI101538B FI101538B (fi) 1998-07-15
FI101538B1 true FI101538B1 (fi) 1998-07-15

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932445A FI101538B1 (fi) 1992-05-29 1993-05-28 Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-metyyli-1-piperatsinyyli)-10H-tieno[2,3-b][1,5]bentsodiatsepiinijohdannaisten valmistamiseksi

Country Status (21)

Country Link
EP (1) EP0582368B1 (xx)
JP (1) JP3219541B2 (xx)
CN (1) CN1043994C (xx)
AT (1) ATE198891T1 (xx)
AU (1) AU668159B2 (xx)
CA (1) CA2097016A1 (xx)
CZ (1) CZ282783B6 (xx)
DE (1) DE69329887T2 (xx)
DK (1) DK0582368T3 (xx)
ES (1) ES2153373T3 (xx)
FI (1) FI101538B1 (xx)
GR (1) GR3035587T3 (xx)
HU (1) HU218278B (xx)
IL (1) IL105827A (xx)
MX (1) MX9303124A (xx)
MY (1) MY109943A (xx)
NO (1) NO305125B1 (xx)
NZ (1) NZ247703A (xx)
PT (1) PT582368E (xx)
RU (1) RU2125574C1 (xx)
TW (1) TW268005B (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
IL126203A (en) * 1996-03-25 2002-12-01 Lilly Co Eli A synergistic painkiller that contains olenzapine and another painkiller
IL126064A0 (en) * 1996-03-25 1999-05-09 Lilly Co Eli Method for treating pain
KR20000004966A (ko) * 1996-03-25 2000-01-25 피터 지. 스트링거 편두통 치료 방법
EA001881B1 (ru) 1996-09-23 2001-10-22 Эли Лилли Энд Компани Форма d дигидрата оланзапина
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
AU719788B2 (en) * 1996-09-24 2000-05-18 Eli Lilly And Company Coated particle formulation
CN104737017B (zh) 2012-08-21 2017-03-08 詹森药业有限公司 利培酮的抗体及其用途
ES2733963T3 (es) 2012-08-21 2019-12-03 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de olanzapina y uso de los mismos
JP6131500B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドン及びパリペリドンのハプテン
US9304126B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of quetiapine
US9611332B2 (en) 2012-08-21 2017-04-04 Janssen Pharmaceutica Nv Antibodies to aripiprazole haptens and use thereof
WO2014031630A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to paliperidone and use thereof
PL2888590T3 (pl) 2012-08-21 2020-11-30 Janssen Pharmaceutica Nv Przeciwciała dla olanzapiny i ich zastosowanie
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
ES2739383T3 (es) 2012-08-21 2020-01-30 Janssen Pharmaceutica Nv Haptenos de paliperidona
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
US20140057297A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Paliperidone Haptens and Use Thereof
US9494607B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to aripiprazole and use thereof
ES2701062T3 (es) * 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
PT3663317T (pt) 2012-08-21 2023-01-23 Janssen Pharmaceutica Nv Anticorpos para haptenos de quetiapina e sua utilização
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
CA3008812A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
FI762646A (xx) * 1975-09-24 1977-03-25 Sandoz Ag
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
TW268005B (xx) 1996-01-11
HU9301579D0 (en) 1993-09-28
CA2097016A1 (en) 1993-11-30
GR3035587T3 (en) 2001-06-29
JPH0687862A (ja) 1994-03-29
CZ282783B6 (cs) 1997-10-15
MX9303124A (es) 1993-11-01
IL105827A0 (en) 1993-09-22
IL105827A (en) 1997-02-18
HU218278B (en) 2000-07-28
PT582368E (pt) 2001-05-31
NZ247703A (en) 1995-07-26
NO931917D0 (no) 1993-05-26
NO305125B1 (no) 1999-04-06
JP3219541B2 (ja) 2001-10-15
CN1085903A (zh) 1994-04-27
CN1043994C (zh) 1999-07-07
EP0582368B1 (en) 2001-01-24
HUT66180A (en) 1994-09-28
AU3980793A (en) 1993-12-02
RU2125574C1 (ru) 1999-01-27
NO931917L (no) 1993-11-30
DK0582368T3 (da) 2001-02-05
AU668159B2 (en) 1996-04-26
DE69329887T2 (de) 2001-05-23
FI932445A (fi) 1993-11-30
EP0582368A1 (en) 1994-02-09
ES2153373T3 (es) 2001-03-01
FI101538B (fi) 1998-07-15
FI932445A0 (fi) 1993-05-28
DE69329887D1 (de) 2001-03-01
ATE198891T1 (de) 2001-02-15
CZ102493A3 (en) 1993-12-15
MY109943A (en) 1997-10-31

Similar Documents

Publication Publication Date Title
FI101538B1 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-metyyli-1-piperatsinyyli)-10H-tieno[2,3-b][1,5]bentsodiatsepiinijohdannaisten valmistamiseksi
KR910018387A (ko) 약제학적 화합물
FI91258C (fi) Menetelmä lääkeaineina käyttökelpoisten 2-(heterosyklyylitio)karbapeneemijohdannaisten valmistamiseksi
HU906402D0 (en) Process for producing tricyclic carbapeneme derivatives an pharmaceutical preparatives containing these compounds as active substance
SE9703205L (sv) Ny kristallform av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno (2,3-b) (1,5)bensodiazepin och framställning därav
EP0255908A3 (en) 7-ûû3-(aminomethyl)-3-alkyl¨-1-pyrrolidinyl¨-quinoline-carboxylic acid-derivatives and pharmaceutical compositions containing them
AU7124391A (en) Condensed thiazole compounds, their production and use
AU636351B2 (en) N-heteroaryl-purin-6-amines, a process for their preparation and their use as medicaments
HUT55397A (en) Process for producing mevalonic acid derivatives comprising thienopyridine ring and pharmaceutical compositions containing such active ingredient
FI92932B (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,2,3,3a,8,8a-heksahydro-1,3a,8-trimetyylipyrrolo/2,3-b/indol-5-yyli-karbonaattiestereiden valmistamiseksi
FI102178B (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,2,3,3a,8,8a-heksahydro-1, 3a,8-trimetyylipyrrolo£2,3-b|indol-5-yylijohdannaisten valmistamiseksi
AU630575B2 (en) Benzodiazepine derivatives
ES2051996T3 (es) Producto farmaceutico.
FI103885B1 (fi) Menetelmä terapeuttisesti aktiivisten 1-bentsyyli-4-fenyylipiperatsiinijohdannaisten valmistamiseksi ja välituotteina käyttökelpoisia yhdisteitä
FR2639944B1 (fr) Nouveaux derives de l'indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU657423B2 (en) Novel piperidine derivatives and process for preparation thereof
FI104078B (fi) Menetelmä terapeuttisesti käyttökelpoisten (3-(1-piperatsinyyli)tieno£2,3-b|- ja -£2,3-c|pyridiinijohdannaisten valmistamiseksi
CA2112980A1 (fr) Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone
KR937000511A (ko) 신규한 화합물
JO1870B1 (en) CO2 derivatives - pyridinyl benzimidazole innovative